JP6276689B2 - 結晶性(1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミン - Google Patents

結晶性(1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミン Download PDF

Info

Publication number
JP6276689B2
JP6276689B2 JP2014517519A JP2014517519A JP6276689B2 JP 6276689 B2 JP6276689 B2 JP 6276689B2 JP 2014517519 A JP2014517519 A JP 2014517519A JP 2014517519 A JP2014517519 A JP 2014517519A JP 6276689 B2 JP6276689 B2 JP 6276689B2
Authority
JP
Japan
Prior art keywords
crystalline form
group
dimethyl
fluoro
indole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014517519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518226A5 (cg-RX-API-DMAC10.html
JP2014518226A (ja
Inventor
グルース・ミヒャエル
クルーゲ・シュテファン
プリュース・シュテファン
Original Assignee
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング filed Critical グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Publication of JP2014518226A publication Critical patent/JP2014518226A/ja
Publication of JP2014518226A5 publication Critical patent/JP2014518226A5/ja
Application granted granted Critical
Publication of JP6276689B2 publication Critical patent/JP6276689B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
JP2014517519A 2011-07-08 2012-07-06 結晶性(1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミン Active JP6276689B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11005587 2011-07-08
EP11005587.8 2011-07-08
PCT/EP2012/002839 WO2013007361A1 (en) 2011-07-08 2012-07-06 Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017003194A Division JP6559165B2 (ja) 2011-07-08 2017-01-12 結晶性(1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミン

Publications (3)

Publication Number Publication Date
JP2014518226A JP2014518226A (ja) 2014-07-28
JP2014518226A5 JP2014518226A5 (cg-RX-API-DMAC10.html) 2015-11-05
JP6276689B2 true JP6276689B2 (ja) 2018-02-07

Family

ID=46717800

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014517519A Active JP6276689B2 (ja) 2011-07-08 2012-07-06 結晶性(1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミン
JP2017003194A Active JP6559165B2 (ja) 2011-07-08 2017-01-12 結晶性(1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017003194A Active JP6559165B2 (ja) 2011-07-08 2017-01-12 結晶性(1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミン

Country Status (23)

Country Link
US (2) US8618156B2 (cg-RX-API-DMAC10.html)
EP (2) EP2729470B1 (cg-RX-API-DMAC10.html)
JP (2) JP6276689B2 (cg-RX-API-DMAC10.html)
CN (2) CN106939005A (cg-RX-API-DMAC10.html)
AR (1) AR087081A1 (cg-RX-API-DMAC10.html)
AU (2) AU2012283449B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014000358A2 (cg-RX-API-DMAC10.html)
CA (1) CA2841032C (cg-RX-API-DMAC10.html)
CY (1) CY1120525T1 (cg-RX-API-DMAC10.html)
DK (2) DK2729470T3 (cg-RX-API-DMAC10.html)
EA (1) EA026750B1 (cg-RX-API-DMAC10.html)
ES (1) ES2641299T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20170968T1 (cg-RX-API-DMAC10.html)
HU (1) HUE033043T2 (cg-RX-API-DMAC10.html)
IL (1) IL230331B (cg-RX-API-DMAC10.html)
LT (1) LT2729470T (cg-RX-API-DMAC10.html)
MX (1) MX2014000297A (cg-RX-API-DMAC10.html)
PL (1) PL2729470T3 (cg-RX-API-DMAC10.html)
PT (1) PT2729470T (cg-RX-API-DMAC10.html)
RS (1) RS56343B1 (cg-RX-API-DMAC10.html)
SI (1) SI2729470T1 (cg-RX-API-DMAC10.html)
TW (1) TWI585092B (cg-RX-API-DMAC10.html)
WO (1) WO2013007361A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8618156B2 (en) * 2011-07-08 2013-12-31 Gruenenthal Gmbh Crystalline (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
CN107427493A (zh) 2015-01-23 2017-12-01 格吕伦塔尔有限公司 用于治疗肝功能受损和/或肾功能受损的受试者的疼痛的Cebranopadol
US20180021304A1 (en) 2015-02-02 2018-01-25 Ratiopharm Gmbh Composition comprising cebranopadol in a dissolved form
MX2018010367A (es) 2016-02-29 2018-12-10 Guenenthal Gmbh Titulacion de cebranopadol.
JP7365073B2 (ja) * 2019-05-21 2023-10-19 ジァンスー フォアフロント ファーマシューティカル カンパニー,リミテッド トレプロスチニルナトリウムの新規な結晶形および製造方法
CN112254496A (zh) * 2020-09-25 2021-01-22 榆林学院 一种煤泥收集装置
WO2024129782A1 (en) 2022-12-12 2024-06-20 Park Therapeutics, Inc. Regimens and compositions useful for alleviating pain
CN122458986A (zh) 2023-02-15 2026-07-24 艾德神经立治疗公司 有用于缓解疼痛的方案和组合物
WO2026035694A1 (en) 2024-08-05 2026-02-12 Adneuris Therapeutics, Inc. Cebranopadol useful for preventing or reducing opioid induced respiratory depression
WO2026161433A1 (en) 2025-01-21 2026-07-30 Adneuris Therapeutics, Inc. Cebranopadol useful for alleviating pain
WO2026161842A1 (en) 2025-01-27 2026-07-30 Adneuris Therapeutics, Inc. Cebranopadol useful for treating pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102005016460A1 (de) * 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
DE102006033109A1 (de) * 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
EP3459533A1 (en) * 2010-08-04 2019-03-27 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain
US8618156B2 (en) * 2011-07-08 2013-12-31 Gruenenthal Gmbh Crystalline (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Also Published As

Publication number Publication date
DK3235821T3 (da) 2020-04-20
CA2841032C (en) 2020-12-15
CY1120525T1 (el) 2019-07-10
EP2729470A1 (en) 2014-05-14
JP2017081981A (ja) 2017-05-18
MX2014000297A (es) 2014-01-31
CA2841032A1 (en) 2013-01-17
HUE033043T2 (hu) 2017-11-28
SI2729470T1 (sl) 2017-10-30
US20130012563A1 (en) 2013-01-10
JP6559165B2 (ja) 2019-08-14
EP3235821B1 (en) 2020-04-08
ES2641299T3 (es) 2017-11-08
WO2013007361A8 (en) 2013-04-04
HRP20170968T1 (hr) 2017-09-22
DK2729470T3 (en) 2017-09-11
TW201311694A (zh) 2013-03-16
US20130231381A1 (en) 2013-09-05
PT2729470T (pt) 2017-10-02
EP3235821A1 (en) 2017-10-25
BR112014000358A2 (pt) 2017-01-10
US8618156B2 (en) 2013-12-31
AU2012283449A8 (en) 2014-03-27
RS56343B1 (sr) 2017-12-29
CN103649094B (zh) 2017-05-24
WO2013007361A9 (en) 2013-12-27
AR087081A1 (es) 2014-02-12
WO2013007361A1 (en) 2013-01-17
PL2729470T3 (pl) 2017-11-30
AU2012283449B2 (en) 2017-04-06
US8765800B2 (en) 2014-07-01
AU2017204572A1 (en) 2017-07-27
TWI585092B (zh) 2017-06-01
CN106939005A (zh) 2017-07-11
JP2014518226A (ja) 2014-07-28
AU2017204572B2 (en) 2018-05-24
EA201400120A1 (ru) 2014-06-30
LT2729470T (lt) 2017-08-25
EA026750B1 (ru) 2017-05-31
CN103649094A (zh) 2014-03-19
IL230331B (en) 2018-11-29
EP2729470B1 (en) 2017-06-21
AU2012283449A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
JP6559165B2 (ja) 結晶性(1r,4r)−6’−フルオロ−N,N−ジメチル−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミン
US8614245B2 (en) Crystalline (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine
AU2012350762B2 (en) Solid forms of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine hydrochloride
AU2012350763B2 (en) Solid forms of (1r,4r)-6'-fluoro-(N,N-dimethyl)-4-phenyl-4',9'-dihydro-3'H-spiro-[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and sulfuric acid
HK1195900B (en) Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
HK1195900A (en) Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
HK1199258B (en) Solid forms of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine hydrochloride

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150703

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160513

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170112

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170220

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180112

R150 Certificate of patent or registration of utility model

Ref document number: 6276689

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533